IP Library › Granted Patent US 12,186,361
Granted Patent B2
US 12,186,361 · App. 17/348,023 · Granted Jan 7, 2025

Method and formulation for inhalation

Inventors: Michelle McIntosh (Parkville, AU); David Morton (Parkville, AU); Tomas Sou (Parkville, AU); Livesey Olerile (Parkville, AU); Richard Prankerd (Parkville, AU)
Assignee: Monash University
A61K38/095A61K9/0073A61K9/0075A61K9/1617A61K9/1623A61K9/1652C07K7/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,361
App. No.
17/348,023
Granted
Jan 7, 2025
Kind
B2
Abstract

This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use.

Claims (20)

1. An inhalable dry powder comprising spray dried particles, the particles comprising:

about 200 IU of oxytocin;

L-leucine in an amount of 10 to 40% by dry weight of said spray dried particles excluding the weight of oxytocin;

the weight remainder of said spray dried particles being an amorphous glass matrix consisting essentially of trehalose; and

wherein the oxytocin is dispersed within the amorphous glass matrix.

2. The inhalable dry powder according to claim 1 , wherein a portion of the L-leucine is located at the surface of the spray dried particles.

3. The inhalable dry powder according to claim 1 , wherein at least 50% of the surface of the spray dried particles is covered by the L-leucine.

4. The inhalable dry powder according to claim 1 , wherein the inhalable dry powder further comprises one or more stabilizing agents.

5. The inhalable dry powder according to claim 1 , wherein more than 40% of the particles of the dry powder have an aerodynamic diameter of less than 5 μm.

6. The inhalable dry powder according to claim 1 , wherein the powder is prepared by a process comprising: preparing an aqueous solution and/or suspension comprising oxytocin, trehalose and L-leucine; and

spray drying the aqueous solution or suspension to produce the inhalable dry powder.

7. The inhalable dry powder of claim 1 or 6 , wherein the amorphous glass matrix is in an amount of 90%.

8. The inhalable dry powder of claim 1 or 6 , wherein the amorphous glass matrix is in an amount of 80%-90%.

9. The inhalable dry powder of claim 1 or 6 , wherein the dry powder is contained within an inhalation device.

10. A method for the treatment or prevention of post partum haemorrhage comprising administering the inhalable dry powder of claim 1 to a subject in need thereof.

11. The method according to claim 10 , wherein the dry powder is inhaled into the pulmonary system via the mouth.

12. The method according to claim 10 , wherein the dry powder is inhaled nasally.

13. A process for the preparation of an inhalable dry powder comprising spray dried particles, comprising:

preparing an aqueous solution or suspension comprising about 200 IU of oxytocin, trehalose and L-leucine; and

spray drying the aqueous solution or suspension to produce the inhalable dry powder, wherein the spray dried particles comprise L-leucine in an amount of 10 to 40% by dry weight of said spray dried particles excluding the weight of oxytocin, the weight remainder of said spray dried particles being an amorphous glass matrix consisting essentially of trehalose; and wherein the oxytocin being dispersed within the amorphous glass matrix.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2023
From: MCINTOSH, MICHELLE; MORTON, DAVID; SOU, TOMAS; OLERILE, LIVESEY; PRANKERD, RICHARD
To: MONASH UNIVERSITY
Reel/Frame 064496/0719 →
Priority Claims (1)
AU 2011903049 · Aug 1, 2011 · national
Continuity (3)
Continuation 15343408 · Nov 4, 2016
Continuation 14236465
Related Publication 20220152145A1 · May 19, 2022
References Cited (57)
US 6258341B1 · Foster et al. · 2001 [cited by applicant]
US 7807200B2 · Lipp · 2010 [cited by examiner]
US 11065297B2 · McIntosh · 2021 [cited by examiner]
US 20040235956A1 · Quay · 2004 [cited by applicant]
US 20060088479A1 · Whitfield · 2006 [cited by examiner]
US 20110045079A1 · Edwards · 2011 [cited by applicant]
US 20110171312A1 · Kuo et al. · 2011 [cited by applicant]
US 20110237508A1 · Amorji et al. · 2011 [cited by applicant]
CN 101669925B · 2011 [cited by applicant]
EP 1402913B1 · 2004 [cited by applicant]
WO 1996023485A1 · 1996 [cited by applicant]
WO 1997003649A1 · 1997 [cited by applicant]
WO 2000033811A1 · 2000 [cited by applicant]
WO 2005079755A2 · 2005 [cited by applicant]
WO 2007014391A2 · 2007 [cited by applicant]
WO 2007068443A1 · 2007 [cited by applicant]
WO 2007095288A2 · 2007 [cited by applicant]
WO 2009046440A1 · 2009 [cited by applicant]
WO 2009143011A1 · 2009 [cited by applicant]
WO 2010033220A2 · 2010 [cited by applicant]
World Health Organization, “WHO Recommendations for the Prevention and Treatment of Postpartum Hemorrhage”, available online http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf, 48 pages at p. 4, 1st … [cited by examiner]
ICF Consulting, “Oxytocin”, Technical Evaluation Report for the USDA National Organic Program, available online at www.ams.usda.gov/sites/default/files/media/Oxytocin%20TR%202005.pdf, 8 pages (2005) (Year: 2005). [cited by examiner]
National Center for Biotechnology Information, PubChem Compound Database, CID=439302, http://pubchem.ncbi.nlm.nih.gov/compound/439302, 51 pages (accessed on Aug. 24, 2015) (Year: 2015). [cited by examiner]
World Health Organization, “WHO Recommendations for the Prevention and Treatment of Postpartum Hemorrhage”, available online http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf, 48 pages at p. 4, 1st … [cited by examiner]
Su et al., Cochrane Database of Systematic Reviews, Issue 3, Art. No. CD005457, pp. 1-35 at p. 3, col. 1, last full paragraph (2007) (Year: 2007). [cited by examiner]
Margo, Kenneth, “Development of polymer-based spray dried particles and cohesion evaluation”, abstract of oral presentation, Monash University Faculty of Pharmacy and Pharmaceutical Sciences Honours Presentations, Apr. … [cited by applicant]
Morton, David, “Droplet-to-particle routes to self-assembled structures for controlled pulmonary delivery”, abstract por oral presentation at Fourth Annual Meeting of Australian Chapter of the Controlled Release Society… [cited by applicant]
Sou, Toma, “The interaction effect of leucine, glycine and alanine on the performance of a mannitol dry powder formulation”, AAPS Abstract, May 17, 2010. [cited by applicant]
Chew, Nora Y.K., et al., “Effect of amino acids on the dispersion of disodium cromoglycate powders”, Journal of Pharmaceutical Sciences, Oct. 2005, vol. 94, No. 10, pp. 2289-2300. [cited by applicant]
Clinton, Hillary R., “Remarks at USAIDS's saving lives at birth development exchange awards ceremony '77 inventions that could save moms and babies”, Jul. 28, 2011, available at http://state.gov/secretary/20092013clinto… [cited by applicant]
Elversson, Jessica, et al., “In situ coating—An approach for particle modification and encapsulation of proteins during spray-drying”, International Journal of Pharmaceutics, Jun. 26, 2006, vol. 323, pp. 52-63. [cited by applicant]
International Search Report for PCT/AU2011/001430, mailed Jul. 2, 2013. [cited by applicant]
Kodas, Toivo T., et al., “Generation of complex metal oxides by aerosol processes: superconducting ceramic particles and films”, Advanced Materials 1989, No. 6, pp. 180-191. [cited by applicant]
Lechuga-Ballestros, David et al., “Trileucine improves aerosol performance and stability of spray-dried powders for inhalation”, Journal of Pharmaceutical Sciences, Jan. 2008, vol. 97, No. 1. [cited by applicant]
Li, H.Y., et al., “The use of amino acids to enhance the aerosolization of spray-dried powders for pulmonary gene therapy”, The Journal of Gene Medicine, Oct. 27, 2007, vol. 7, pp. 343-353. [cited by applicant]
McIntosh, Michelle, “ Low cost, needle-free and non-refrigerated treatment for post-partum haemorrhage”, presentation at Saving Lives at Birth Global Challenge Forum, Jul. 27, 2011. [cited by applicant]
Minne, Antoine, et al., “Optimization of the aerosolization properties of an inhalation dry powder based on the selection of excipients”, European Journal of Pharmaceutics and Biopharmaceutics, Jun. 24, 2008, vol. 70, p… [cited by applicant]
Monash University, “New drug dose to reduce maternal deaths”, Monash University News Website, Mar. 1, 2011, available at http://monash.edu.au/news/show/new-drug-dose-to-reduce-maternal-deaths, retrieved Jul. 1, 2014. [cited by applicant]
Monash University, “Saving lives at birth: a grand challenge”, Monash University News Website, Jul. 22, 2011, available at http://monash.edu/news/show/saving-lives-at-birth-a-grand-challenge, retrieved Jun. 17, 2014. [cited by applicant]
Monash University, “Monash research acknowledged by Hillary Clinton”, Monash University News Website, Jul. 29, 2011, available at http://monash.news/show/a-life-saving-challenge-with-a nod-from-hillary-clinton, retrived… [cited by applicant]
Nassta, Gemma, “Development, characterization, and evaluation of oxytocin spray dried particles”, abstract of oral presentation, Monash University Faculty of Pharmacy and Pharmaceutical Sciences Honours Presentations, A… [cited by applicant]
O'Donnell, Kevin P., et al., “Macro- and microstructure of the airways for drug delivery”, Controlled Pulmonary Drug Delivery, Advances in Delivery Science and Technology, Jan. 2011, pp. 1-19. [cited by applicant]
Olsson, Bo, et al., “Pulmonary drug metabolism, clearance, and absorption”, Controlled Pulmonary Drug Delivery, Advances in Delivery Science and Technology, Jan. 2011, pp. 21-50. [cited by applicant]
Rabbani, Naumana R., et al., “ The influence of formulation components on the aerosolization properties of spray-dried powders”, Journal of Controlled Release, Oct. 13, 2005, vol. 110, pp. 130-140. [cited by applicant]
Raula, Janne, et al., “Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders”, International Journal of Pharmaceutics, Aug. 22, 2008, vol. 365, pp. 18-25. [cited by applicant]
Raula, Janne, et al., “Investigations on the humidity-induced transformations of salbutamol sulphate particles coated with L-leucine”, Pharmaceutical Research, Jun. 27, 2008, vol. 25, pp. 2250-2261. [cited by applicant]
Sakagami, Masahiro, et al., “Targeted drug delivery through the respiratory system: molecular control on lung absorption and disposition”, Controlled Pulmonary Drug Delivery, Advances in Delivery Science and Technology,… [cited by applicant]
Seville, P.C., et al., “Amino acid-modified spray-dried powders with enhanced aerosolization properties for pulmonary drug delivery”, Powder Technology, Apr. 5, 2007, vol. 178, pp. 40-50. [cited by applicant]
Shin Nippon Biomedical Laboratories, Ltd., “Conclusion of licensing agreement with Pastorus Pharma, LLC: Intranasal oxytocin for the treatment of autism”, Feb. 10, 2011, media release. [cited by applicant]
Shur, Jagdeep, et al., “Cospray-dried unfractionated heparin with L-leucince as a dry powder inhaler mucolytic for cystic fibrosis therapy”, Journal of Pharmaceutical Sciences, Nov. 2008, vol. 97, No. 11. [cited by applicant]
Sou, Tomas, “An investigation on the interaction effect of amino acids on the performance of a mannitol dry powder formulations using a design of experiment approach”, abstract of poster presentation at eighth meeting o… [cited by applicant]
Sou, Tomas, “The interaction effect of leucine, glycine, and alanine on the performance of a mannitol dry powder formulation”, AAPS abstract, May 17, 2010. [cited by applicant]
Vehring, Reinhard, “Pharmaceutical particle engineering via spray drying”, Pharmaceutical Research, Nov. 28, 2007, vol. 25, No. 5, pp. 999-1022. [cited by applicant]
Zhao, Min, et al., “Formulation, characteristics, and aerosolization performance of azithromycin DPI prepared by spray-drying”, Powder Technology, Mar. 7, 2008, vol. 187, pp. 214-221. [cited by applicant]
Hrbas, P., et al., “Effect of some oxytocin analogues on matriuresis in rats”, Endocrinologia Experimentalis, 1980, vol. 14, pp. 151-157. [cited by applicant]
Gimpl et al., The Oxytocin Receptor System: Structure, Function and Regulation. Physiol. Rev. 81:629-683 ay p. 631, col. 1, Ist paragrah, Table 1, 2001. [cited by applicant]
Sawyer et al., Synthetic Analogs of Oxytocin and the Vasopressins. Annu. Rev. Pharmacol. 13:5-17 at p. 5, 2nd paragraph (1973). [cited by applicant]